Literature DB >> 28860006

Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.

Barbara A Goff1, Kathy Agnew2, Moni Blazej Neradilek3, Heidi J Gray2, John B Liao2, Renata R Urban2.   

Abstract

OBJECTIVES: To assess a simple algorithm of CA125, HE4 and Symptom Index to predict ovarian cancer in women with a pelvic mass.
METHODS: This was a prospective study of women referred to a gynecologic oncology clinic for surgical evaluation of a pelvic mass. Preoperatively, women completed a SI and had serum markers drawn. Results were correlated with pathology. A triple screen was considered positive if at least 2 of the 3 markers were abnormal (positive SI, CA125≥35U/mL, HE4≥140pmol/L).
RESULTS: 218 patients enrolled in the study. 66 patients (30%) had ovarian or fallopian tube cancer (97% epithelial), 124 (57%) had benign masses, 17 (8%) had borderline tumors, and 11 (5%) had metastatic disease. The SI, CA125 and HE4 were positive in 87.9%, 74.2% and 60.6% of ovarian cancer patients, respectively. Of the 112 women with a positive SI 58 (52%) had ovarian cancer and 75 (67%) had non-benign masses. Excluding borderline and metastatic cancers the sensitivity of the triple screen was 79%; specificity 91%, PPV 83% and NPV 89%. CA125 alone had a sensitivity, specificity, PPV and NPV of 79%, 76%, 63% and 87% respectively. Requiring only one of the three tests to be abnormal resulted in a sensitivity of 97% but specificity dropped to 50%.
CONCLUSIONS: An algorithm using SI, CA125 and HE4 has good performance statistics for predicting cancer in women with pelvic masses. The triple screen has higher specificity and PPV than CA125 alone but similar sensitivity and NPV for predicting ovarian cancer.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  CA125; HE4; Ovarian cancer; Symptom index

Mesh:

Substances:

Year:  2017        PMID: 28860006     DOI: 10.1016/j.ygyno.2017.08.020

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Use of a human embryonic stem cell model to discover GABRP, WFDC2, VTCN1 and ACTC1 as markers of early first trimester human trophoblast.

Authors:  Rowan M Karvas; Samuel McInturf; Jie Zhou; Toshihiko Ezashi; Danny J Schust; R Michael Roberts; Laura C Schulz
Journal:  Mol Hum Reprod       Date:  2020-06-01       Impact factor: 4.025

2.  Identification of six serum antigens and autoantibodies for the detection of early stage epithelial ovarian carcinoma by bioinformatics analysis and liquid chip analysis.

Authors:  Yupeng Zou; Li Li
Journal:  Oncol Lett       Date:  2018-06-26       Impact factor: 2.967

3.  Usefulness of HE4 protein in differentiation of pelvic masses in woman.

Authors:  Andrzej Brenk; Piotr Bodzek; Mikołaj Baliś; Aleksandra Barbachowska; Iwona Janosz; Anita Olejek
Journal:  Prz Menopauzalny       Date:  2019-04-09

4.  High expression of sperm-associated antigen 5 correlates with poor survival in ovarian cancer.

Authors:  Mei Zhang; Ling Sha; Ning Hou; Chuanbing Shi; Lin Tan
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

5.  Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial.

Authors:  Vincent Dochez; Mélanie Randet; Céline Renaudeau; Jérôme Dimet; Aurélie Le Thuaut; Norbert Winer; Thibault Thubert; Edouard Vaucel; Hélène Caillon; Guillaume Ducarme
Journal:  J Clin Med       Date:  2019-10-25       Impact factor: 4.241

6.  A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.

Authors:  Lu Mao; Yong Tang; Ming-Jing Deng; Chun-Tao Huang; Dong Lan; Wen-Zheng Nong; Li Li; Qi Wang
Journal:  J Clin Lab Anal       Date:  2022-01-07       Impact factor: 2.352

7.  Extremely high serum CA19-9 level along with elevated D-dimer in assisting detection of ruptured ovarian endometriosis.

Authors:  Ting Shuang; Yiran Wang; Lanbo Zhao; Kailu Zhang; Panyue Yin; Lin Guo; Wei Jing; Xue Feng; Qiling Li
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

8.  WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation.

Authors:  Yaoyi Xiong; Lushun Yuan; Song Chen; Huimin Xu; Tianchen Peng; Lingao Ju; Gang Wang; Yu Xiao; Xinghuan Wang
Journal:  Cell Death Dis       Date:  2020-07-16       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.